NYTIMES (Liz Krieger) - Peptides, GLP-1 Drugs and Botox: Needles Are Everywhere Now
Weight-loss drugs, peptides, I.V.F. As sharps migrate out of doctors’ offices, even needle-phobics are willing to embrace shots.
NYTIMES (Gina Kolata) - How One Woman With a Very Rare Disease Secured a Clinical Trial
Through sheer determination, Neena Nizar has become the first patient in a clinical trial testing a treatment for her disease — one so rare it affects just 30 people worldwide.
NPR (Will Stone) - Cialis is an erectile dysfunction drug. Could it also help you live longer?
In some wellness circles, tadalafil is promoted as a longevity drug. There is evidence showing a link between it and a lower risk of death in men, but there are no well-controlled trials in humans.
STRIPES (Matthew M. Burke) - THC drug eliminated nightmares for over a third of PTSD patients in German trial | Stars and Stripes
The 10-week study of the drug dronabinol is believed to be the first of its kind to study the drug’s impact on PTSD-related nightmares.
ABCNEWS - FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?
An advisory committee for the Food and Drug Administration has narrowly voted to add six peptides to a drug compounding list.
THENATIONALPULSE (Pulse Wires) - DATA: GLP-1 Medications Reduce Employee Sick Days by 17%.
A new study published has revealed that GLP-1 drugs, such as Ozempic and Wegovy, reduced long-term sick leave by almost 20 percent.
A new study has highlighted the apparent economic benefits of GLP-1 medications like Ozempic and Wegovy, such as reducing long-term absences, saving money for employers and governments, and boosting productivity. PULSE POINTS WHAT HAPPENED: A new study has revealed that GLP-1 weight-loss drugs reduced long-term sick leave by almost 20 percent. DETAIL: According to a new study by the National Bureau of Economic Research, GLP-1 drugs reduced long-term sick leave by 17 percent . compared to those who did not take them. The study defined long-term sick leave as health-related absences longer than 30 days. The study analyzed data from Denmark, where long-term sick leave, which is also defined as longer than 30 days, is government-funded. The…Open
NYTIMES (Dani Blum) - What Older Adults Should Know About GLP-1 Drugs as Medicare Coverage Expands
A Medicare pilot beginning Wednesday will broaden access to medications like Wegovy and Zepbound. There are unique risks for those over 65.
NEWSNATIONNOW (Zach Kaplan) - GLP-1 drugs linked to low blood pressure risk, Northwestern study finds
A senior author called the findings "statistically significant," citing the potential severity of low blood pressure events.
NYTIMES (Dana G. Smith) - Could GLP-1 Drugs Help You Live Longer?
Experts are intrigued by the theory. Here’s what early research suggests.
NEWSNATIONNOW (Adelaide Taylor) - GLP-1s may be misused by patients with eating disorders: Study
According to the study, the prevalence of GLP-1 use is higher among people with eating disorders than the general population.